Median time to progression Approximately every 3 weeks until disease progression [clinicaltrials_resource:0dee495014db4415d2482064adcaa2e5]

Median time to progression Approximately every 3 weeks until disease progression [clinicaltrials_resource:0dee495014db4415d2482064adcaa2e5]

Carboplatin + pemetrexed + bevacizumab
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:0dee495014db4415d2482064adcaa2e5
clinicaltrials:NCT00234052
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Median time to progression Approximately every 3 weeks until disease progression [clinicaltrials_resource:0dee495014db4415d2482064adcaa2e5]

Carboplatin + pemetrexed + bevacizumab
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:0dee495014db4415d2482064adcaa2e5
Bio2RDF identifier
0dee495014db4415d2482064adcaa2e5
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:0dee495014db4415d2482064adcaa2e5
measure [clinicaltrials_vocabulary:measure]
Median time to progression
time frame [clinicaltrials_vocabulary:time-frame]
Approximately every 3 weeks until disease progression
description
Carboplatin + pemetrexed + bevacizumab
identifier
clinicaltrials_resource:0dee495014db4415d2482064adcaa2e5
title
Median time to progression Approximately every 3 weeks until disease progression
@en
inDataset
type
label
Median time to progression App ...... e495014db4415d2482064adcaa2e5]
@en